Pergolizzi J V, Raffa R B, LeQuang J A
Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
University of Arizona College of Pharmacy, Tucson, AZ, USA.
J Clin Pharm Ther. 2016 Dec;41(6):592-593. doi: 10.1111/jcpt.12444. Epub 2016 Aug 31.
The Centers for Disease Control and Prevention (CDC) have published guidelines for opioid prescribing, with the goal of helping guide clinicians to make safe prescribing choices. In the form of 12 statements, the CDC offers guidance that at times is not supported by the evidence or introduces new concepts (such as a requirement that opioids improve function). Our objective was to examine the new guidelines in terms of how well they could strike the balance between keeping opioids accessible to those who need them while appropriately restricting their use.
The CDC guidelines offer some reasonable and laudable guidance, but they also make some recommendations which are not supported by current scientific evidence. We also noted that the urgent need for greater education among opioid prescribers was not addressed in the new guidelines.
美国疾病控制与预防中心（CDC）发布了阿片类药物处方指南，旨在帮助指导临床医生做出安全的处方选择。CDC以12条声明的形式提供指导意见，然而这些意见有时缺乏证据支持，或者引入了新的概念（例如要求阿片类药物改善功能）。我们的目标是评估这些新指南在满足有需求者获取阿片类药物的同时，合理限制其使用方面的平衡程度。
CDC指南提供了一些合理且值得称赞的指导，但也提出了一些没有当前科学证据支持的建议。我们还注意到，新指南未涉及对阿片类药物处方医生加强教育的迫切需求。
